CurrentAdvanced HealthPolicy N/A

Colony-Stimulating Factor (CSF) Guidelines

Customize your policy alerts

Sign up for all advancedhealth policy alerts

Know when advancedhealth releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage and clinical use of colony-stimulating factors for prevention and treatment of neutropenia in patients receiving chemotherapy, undergoing autologous progenitor cell transplantation, or experiencing specified neutropenia syndromes.

Policy Summary

PayerAdvanced Health

PolicyColony-Stimulating Factor (CSF) Guidelines

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument the primary chemotherapy regimen and its known febrile-neutropenia risk before requesting CSF prophylaxis.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥20%Primary prophylaxis indication

10–20%Consideration range

ANC <100/mcLSevere neutropenia criterion

>65 yearsAge criterion

>10 daysNeutropenia duration

Policy Summary

PayerAdvanced Health

PolicyColony-Stimulating Factor (CSF) Guidelines

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument the primary chemotherapy regimen and its known febrile-neutropenia risk before requesting CSF prophylaxis.

SourceLink

On This Page

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAdvanced HealthPolicy N/A

Colony-Stimulating Factor (CSF) Guidelines

Customize your policy alerts

Sign up for all advancedhealth policy alerts

Know when advancedhealth releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAdvanced Health

PolicyColony-Stimulating Factor (CSF) Guidelines

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument the primary chemotherapy regimen and its known febrile-neutropenia risk before requesting CSF prophylaxis.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥20%Primary prophylaxis indication

10–20%Consideration range

ANC <100/mcLSevere neutropenia criterion

>65 yearsAge criterion

>10 daysNeutropenia duration

Policy Summary

PayerAdvanced Health

PolicyColony-Stimulating Factor (CSF) Guidelines

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument the primary chemotherapy regimen and its known febrile-neutropenia risk before requesting CSF prophylaxis.

SourceLink

On This Page

Medical Necessity Criteria

Primary Prophylaxis — Chemotherapy Risk

Coverage may be considered when the chemotherapy regimen meets the applicable febrile-neutropenia risk threshold.

ONE of the following

The primary chemotherapeutic regimen is known to produce febrile neutropenia at least 20% of the time.
The primary chemotherapeutic regimen is known to produce febrile neutropenia 10% to 20% of the time, and less myelosuppressive chemotherapy or dose reduction has been considered as an alternative.

Secondary Prophylaxis

Secondary prophylaxis is considered after severe or febrile neutropenia, with dose reduction as the primary therapeutic option except in the setting of a curable tumor where maintaining dose intensity is clinically necessary.

ALL of the following

The patient experienced an episode of severe or febrile neutropenia during chemotherapy.
ONE of the following
- Dose reduction is being used or has been considered as the primary strategy.
- The patient has a curable tumor, such as a germ-cell tumor, for which maintaining chemotherapy dose intensity is clinically necessary.

Febrile Neutropenia Treatment

CSF may be considered for treatment of febrile neutropenia only when at least one qualifying circumstance is present.

ONE of the following

The patient received prophylactic filgrastim or sargramostim.
The patient is high risk and did not receive prophylactic CSF.
- No prophylactic CSF was administered.
- At least one high-risk feature is present.
  - Age greater than 65 years.
  - Sepsis.

Chemotherapy Dose Intensity or Schedule

CSF may be used to increase chemotherapy dose intensity or schedule only when the improved outcome from that increase has been documented in a clinical trial.

ALL of the following

CSF is being used to increase chemotherapy dose intensity or alter the chemotherapy schedule.
A clinical trial has documented improved clinical outcomes from the increased dose intensity or schedule.

Autologous Progenitor Cell Transplantation

CSF other than pegfilgrastim may be used in connection with autologous progenitor cell transplantation.

ONE of the following

Mobilization of peripheral blood progenitor cells for autologous transplantation.
Administration after infusion of autologous progenitor cells.

Cyclic, Congenital, and Idiopathic Neutropenia

CSF is indicated for treatment of qualifying chronic neutropenia syndromes.

ONE of the following

Cyclic neutropenia.
Congenital neutropenia.
Idiopathic neutropenia.

Myelodysplastic Syndromes

CSF may be indicated for selected patients with myelodysplastic syndromes when the response is clinically demonstrated.

ALL of the following

The patient has a myelodysplastic syndrome with severe neutropenia.
The patient has recurrent infections or another clinically significant consequence of neutropenia.
A significant clinical response to CSF is documented.

CSF is not indicated in patients who are acutely neutropenic but afebrile.

CSF is not indicated for treatment of febrile neutropenia unless the patient received prophylactic filgrastim or sargramostim, or is a high-risk patient who did not receive prophylactic CSF.

CSF is not indicated to increase chemotherapy dose intensity or schedule unless improved outcome from the increased intensity has been documented in a clinical trial.

CSF is not indicated in patients receiving concomitant chemotherapy and radiation therapy.

There is no evidence of clinical benefit from routine, continuous CSF use for recurrent infections. CSF should be used only when a significant response is documented.

Clinical Thresholds

Primary prophylaxis febrile-neutropenia risk

Risk thresholdAt least 20%

Applies toKnown febrile-neutropenia risk from the primary chemotherapeutic regimen

Policy implicationPrimary CSF prophylaxis is indicated when the regimen is known to produce febrile neutropenia at least 20% of the time

Consideration range for primary prophylaxis

Risk range10–20%

Applies toKnown febrile-neutropenia risk from the primary chemotherapeutic regimen

Required consideration

Documentation and Utilization Guidance

Documentation Required

Primary Prophylaxis by Regimen Risk

Use primary CSF prophylaxis when the planned chemotherapeutic regimen is known to cause febrile neutropenia in at least 20% of patients.

For regimens with a 10–20% febrile-neutropenia risk, consider CSF only after evaluating less myelosuppressive chemotherapy or dose reduction.
Document the regimen and its expected febrile-neutropenia risk.

Documentation Required

Secondary Prophylaxis After Neutropenia

After an episode of severe or febrile neutropenia, consider chemotherapy dose reduction as the primary secondary-prophylaxis strategy.

Exceptions may apply for curable tumors, such as germ-cell tumors, when maintaining dose intensity is clinically important.
No disease-free or overall-survival benefit has been documented for dose maintenance with CSF in the general setting.

Policy Background

Colony-stimulating factors support neutrophil production and are used selectively to prevent or manage chemotherapy-associated neutropenia. Coverage depends on the regimen’s expected febrile-neutropenia risk, the patient’s risk factors and prior neutropenia history, the treatment setting, and evidence that CSF improves outcomes. The guideline also addresses use during autologous progenitor cell transplantation and for cyclic, congenital, idiopathic, and selected myelodysplastic-syndrome-associated neutropenia.

Severe neutropenia with absolute neutrophil count less than 100/mcL.

Neutropenia is expected to last more than 10 days.

Invasive fungal infection.

Another clinically documented infection.

Hospitalization at the time of fever.

A prior episode of febrile neutropenia.

Explore less myelosuppressive chemotherapy or dose reduction before using CSF

Severe neutropenia high-risk criterion

Absolute neutrophil count<100/mcL

Clinical contextSevere neutropenia during febrile neutropenia

Policy implicationQualifies as a high-risk feature when considering CSF treatment for febrile neutropenia

Age high-risk criterion

Age threshold>65 years

Clinical contextPatient with febrile neutropenia who did not receive prophylactic CSF

Policy implicationQualifies as a high-risk feature for consideration of CSF treatment

Expected neutropenia duration high-risk criterion

Expected duration>10 days

Clinical contextNeutropenia expected to continue for more than 10 days during febrile neutropenia

Policy implicationQualifies as a high-risk feature for consideration of CSF treatment

Prior Authorization

Treatment of High-Risk Febrile Neutropenia

CSF treatment for febrile neutropenia is supported only for patients who received prophylactic filgrastim or sargramostim, or for high-risk patients who did not receive prophylactic CSF.

High-risk features include age >65 years, sepsis, absolute neutrophil count <100/mcL, neutropenia expected to last >10 days, pneumonia, invasive fungal infection, another clinically documented infection, hospitalization at fever onset, or a prior episode of febrile neutropenia.

Documentation Required

Autologous Progenitor Cell Transplantation

Use CSF other than pegfilgrastim for autologous progenitor cell transplantation to mobilize peripheral blood progenitor cells and after progenitor-cell infusion.

Document the transplantation or mobilization indication and the applicable treatment phase.

Documentation Required

Specified Neutropenia Syndromes

CSF is indicated for the treatment of cyclic, congenital, and idiopathic neutropenia.

Document the specific neutropenia syndrome being treated.

Documentation Required

Selected Myelodysplastic Syndrome Use

CSF may be indicated for selected patients with myelodysplastic syndromes who have severe neutropenia, recurrent infections, and a significant clinical response to treatment.

Document the severity of neutropenia, recurrent infections, and the patient’s response.

Step Therapy

Consider Less Myelosuppressive Alternatives

For regimens with a 10–20% risk of febrile neutropenia, first consider less myelosuppressive chemotherapy or another clinically appropriate alternative.

CSF should not be used as the default response when the risk is attributable to the chemotherapy regimen.
Document why less myelosuppressive alternatives were considered or are not appropriate.

Unsupported block type: step_therapy réasoning?

Documentation Required

Chemotherapy Risk Documentation

Document the chemotherapy regimen and its expected febrile-neutropenia risk whenever CSF is requested for primary prophylaxis.

For risk below 20%, document the clinical rationale, including consideration of less myelosuppressive therapy or dose reduction.
For risk at least 20%, identify the source or basis for the regimen-specific risk estimate.

Documentation Required

Secondary Prophylaxis Rationale

For secondary prophylaxis, document the prior severe or febrile-neutropenia episode, consideration of dose reduction, and the reason a qualifying exception supports CSF use.

When maintaining dose intensity for a curable tumor, document the tumor type and clinical rationale.

Documentation Required

High-Risk Febrile Neutropenia Documentation

For treatment of febrile neutropenia, document either prior prophylactic filgrastim or sargramostim use or the high-risk feature supporting treatment.

Record the applicable high-risk feature, such as age >65 years, sepsis, ANC <100/mcL, expected duration >10 days, pneumonia, invasive fungal infection, another documented infection, hospitalization at fever onset, or prior febrile neutropenia.

Unsupported block type: documentation

Denial Risk

Inadequate Primary Prophylaxis Indication

Primary prophylaxis with CSF is unsupported when the regimen’s febrile-neutropenia risk is below 20% unless a qualifying rationale is documented.

For a 10–20% risk, documentation must show consideration of less myelosuppressive chemotherapy or dose reduction.
CSF is not indicated with concomitant chemotherapy and radiation therapy.

Denial Risk

Failure to Consider Dose Reduction

Secondary prophylaxis is unsupported when dose reduction was not considered and no qualifying curable-tumor or other documented exception applies.

Routine CSF-supported dose maintenance without documented benefit is not sufficient.

Denial Risk

Febrile Neutropenia Lacks Qualifying Risk

Treatment of febrile neutropenia is unsupported without documentation of prior prophylactic filgrastim or sargramostim or a qualifying high-risk feature.

CSF is not indicated for acute neutropenia when the patient is afebrile.
Do not use CSF with concomitant chemotherapy and radiation therapy.

Denial Risk

Unsupported Dose-Intensity Use

CSF use to increase chemotherapy dose intensity or preserve schedule is unsupported without evidence from a clinical trial showing improved outcomes.

Document the trial, regimen, patient population, and outcome supporting the requested dose-intensity strategy.

Denial Risk

No Documented Response

Routine continuous CSF use for recurrent infections is unsupported when no significant clinical response has been documented.

For continued treatment, document a significant response and its clinical relevance.
Absence of documented response supports discontinuation or denial of routine continuous use.